IRF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications
Abstract
No abstract availableKeywords
Funding Information
- Hunan Province Health Commission (W20243031)
- Hunan Province Health Commission (D202303047052)
- Health Commission of Hunan Province
- Hunan Provincial Natural Science Foundation (2023JJ40850)
- Hunan Provincial Natural Science Foundation (2022JJ30850)
This publication has 49 references indexed in Scilit:
- Roles of IRF4 in various immune cells in systemic lupus erythematosusInternational Immunopharmacology, 2024
- Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patientsHuman Pathology, 2023
- Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshopVirchows Archiv, 2023
- Puppet masters of B‐cell progenitor acute lymphoblastic leukemia: The preB cell receptor and the interleukin 7 receptor αEuropean Journal of Immunology, 2023
- Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer’s ring in adultsVirchows Archiv, 2023
- The dynamic functions of IRF4 in B cell malignanciesClinical and Experimental Medicine, 2022
- Follicular lymphoma and marginal zone lymphoma: how many diseases?Virchows Archiv, 2022
- Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesisCellular Immunology, 2022
- Lineage- and Stage-Specific Oncogenicity of IRF4Experimental Hematology, 2022
- Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myelomaHematological Oncology, 2022